Novel Adjuvant
Go Back
Novel Adjuvant
The adjuvant is a substance used in combination with an antigen to assist in antigen presentation and enhance the immune response. Traditionally, only aluminium adjuvants have been widely used in vaccine development. Since the 21st century, novel adjuvants have gradually become widely used in the vaccine industry to create vaccine products that can stimulate more and broader immune responses to deal with major diseases with a heavy burden. According to Frost Sullivan, as of July 6, 2021, only five novel adjuvants -- AS01, AS03, AS04, CpG1018 and MF59 -- had been in the public domain for more than 20 years. With this platform, Recbio is one of the few companies that can develop new adjuvants that match all of the FDA approved adjuvants. Thanks to this capability, the company is not dependent on any specific adjuvant supplier. The platform also enables the company to discover and deploy novel adjuvants in the next generation of vaccine candidates.
